“There's 3 different levels of dosing…so this does provide you with a mechanism for titration if you're going to be using that in your patients,” says Jesse N. Mills, MD.

In this video, Jesse N. Mills, MD, discusses the important findings from the study, “Subcutaneous Testosterone Enanthate and the Effect of Body Mass Index on Serum Testosterone in Men with Testosterone Deficiency,” presented recently at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting. Mills is an associate clinical professor of urology at the David Geffen School of Medicine, the director of the UCLA division of Andrology, the director of the Men’s Clinic and the chief of UCLA Santa Monica Urology, University of California, Los Angeles

Is neoadjuvant therapy a pathway to improved outcomes in localized kidney cancer?

At the 2023 SUO Annual Meeting, Grant Stewart, MD, PhD, discussed the potential of neoadjuvant therapy as a tool to help optimize the management of patients with localized kidney cancer.

Dr. Fizazi discusses potential of darolutamide-based triplet regimen for metastatic hormone-sensitive prostate cancer

“Obviously, patients benefit [from this regimen]. Not only can they enjoy longer life, but also their cancer is pretty much under control for a longer time, which is great,” says Karim Fizazi, MD, PhD

TULSA compared with radical prostatectomy in phase 3 trial

The phase 3 CAPTAIN trial was launched following the pivotal TACT trial, which showed that TULSA provided durable disease control with low toxicity at 3 years’ follow-up in men with localized prostate cancer.

Rollover data from OLYMPUS trial show long-term durability of LG-UTUC treatment

"Jelmyto provides an effective and durable kidney-sparing treatment option and should be considered as primary therapy for adult patients with LG-UTUC,” said Phillip Pierorazio, MD.

Obesity not linked to lower renal function following partial nephrectomy

“So I think what we can take away from this study is that just because your patient [has a higher BMI], doesn't mean that they're a poor candidate for a partial nephrectomy,” said Lachlan Shiver.

Long-term follow-up supports pembrolizumab monotherapy in BCG-unresponsive NMIBC

Pembrolizumab monotherapy continued to demonstrate durable complete responses, while rates of upstaging at the time of radical cystectomy were consistent with previous findings in the KEYNOTE-057 trial in patients with BCG-unresponsive NMIBC.